ストックスクリーナーアプリを入手
1.42
2.16%
0.03
前日終値:
$1.39
開ける：
$1.39
24時間の取引高:
37,935
Relative Volume:
0.56
時価総額：
$73.02M
収益：
$18.11M
当期純損益:
$-18.95M
株価収益率:
-3.2457
EPS:
-0.4375
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.19%
1か月 パフォーマンス:
-13.41%
6か月 パフォーマンス:
-52.82%
1年 パフォーマンス:
-39.57%
1日の値動き範囲:
$1.39
$1.45
1週間の範囲:
$1.36
$1.60
52週間の値動き範囲:
$1.325
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
ADAG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.42 | 73.02M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 開始されました | China Renaissance | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
Adagene Inc Adr (ADAG) 最新ニュース
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire
Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan
FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com
Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World
Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire
Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq
Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - BERNAMA
Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times
Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan
Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire
Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan
Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat
Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Inc Adr (ADAG) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):